B
Brian P. Danysh
Researcher at Broad Institute
Publications - 37
Citations - 1070
Brian P. Danysh is an academic researcher from Broad Institute. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 12, co-authored 21 publications receiving 696 citations. Previous affiliations of Brian P. Danysh include Rice University & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Abstract 1789: Chromatin modifier alterations confer resistance to endocrine deprivation and CDK4/6 inhibitors in ER+ breast cancer and drive convergent evolution in patient autopsy lesions
Elizaveta S. Leshchiner,Ignaty Leshchiner,Elizabeth E. Martin,Christopher S. Chen,Thomas Zhang,Christopher J. Pinto,Kahn Rhrissorrakrai,Filippo Utro,Chaya Levovitz,Raquel A. Jacobs,Brian P. Danysh,Kara Slowik,Maida Williams Broudo,Laxmi Parida,Dejan Juric,Gad Getz +15 more
TL;DR: It is suggested that KMT2C mutations may be a mechanism of acquired resistance to CDK 4/6 inhibitor combinations, and subsequent treatment with therapies directed towards ER or CDK4/6 pathways may be ineffective and other treatment avenues need to be developed.
Journal ArticleDOI
Evaluation of tumor mutation burden (TMB) in tumor (tDNA) and plasma cell free DNA (cfDNA) in patients (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with a combination of cetuximab and nivolumab (C+N).
C. Chung,Nicholas J. Haradhvala,Laxmi Parida,Jiannong Li,Robbert J.C. Slebos,XiaoFei Song,Ritu Chaudhary,Maria I. Poole,Robin Park,Kedar Kirtane,Conor E. Steuer,Nabil F. Saba,Priyanka Bhateja,James W. Rocco,M. Bonomi,Brian P. Danysh,Gad Getz,Aik Choon Tan +17 more
TL;DR: In this article , the authors evaluated TMB from whole-exome sequencing (WES) of cfDNA as a surrogate for tDNA TMB in R/M HNSCC pts treated with C+N.
Journal ArticleDOI
Resistance to the Non-Covalent BTK Inhibitor Pirtobrutinib
Aishath S Naeem,Filippo Utro,Qing Wang,Justin Cha,Mauno Vihinen,Stephen P. Martindale,Yinglu Zhou,Svitlana Tyekucheva,Annette S. Kim,Stacey M. Fernandes,Rayan Fardoun,Gordon Saksena,Kahn Rhrissorrakrai,Chaya Levovitz,Brian P. Danysh,Kara Slowik,Raquel A. Jacobs,Matthew S. Davids,Rula Zain,Edvard Smith,Ignaty Leshchiner,Laxmi Parida,Gad Getz,Jennifer R. Brown +23 more
TL;DR: Pirtobrutinib is a non-covalent BTK inhibitor (BTKi) designed to maintain activity despite the most common resistance mutation to covalent inhibitors, at BTK C481 as discussed by the authors .
Journal ArticleDOI
Abstract 3874: Genomic mechanisms of resistance to tyrosine kinase inhibitors (TKIs) in HER2+ metastatic breast cancer (HER2+ MBC)
Heather A. Parsons,Conor Messer,K. Santos,Brian P. Danysh,Melissa E. Hughes,Ashka Patel,Raquel A. Jacobs,Kara Slowik,Julian M. Hess,Chip Stewart,Kahn Rhrissorrakrai,Filippo Utro,Chaya Levovitz,Nikhil Wagle,Jose Pablo Leone,Rachel A. Freedman,Laxmi Parida,Ian E. Krop,Gad Getz,Nan Lin +19 more
TL;DR: Parsons et al. as mentioned in this paper performed whole exome sequencing (WES) on 19 tumor biopsies and 64 cfDNA samples from 25 patients with HER2+ metastatic breast cancer (HER2+MBC).
Journal ArticleDOI
Abstract 3575: Differential dynamics of response at single cell resolution between axi-cel and tisa-cel CAR-T therapy in refractory B-cell lymphomas
Nicholas J. Haradhvala,Mark B. Leick,Katie Maurer,Satyen H. Gohil,Rebecca C. Larson,Estelle Yao,Matthew J. Frigault,Shuqiang Li,Kenneth J. Livak,Kahn Rhrissorrakrai,Filippo Utro,Chaya Levovitz,Raquel A. Jacobs,Kara Slowik,Brian P. Danysh,Laxmi Parida,Catherine J. Wu,Gad Getz,Marcela V. Maus +18 more
TL;DR: This represents the largest CAR-T scRNAseq cohort established thus far and provides important insights into (i) the temporal dynamics of a successfulCAR-T response, (ii) the molecular phenotypes of CAR-t cells with different costimulatory domains, and (iii) the capacity for small increases in CAR- Tregs to drive relapse.